Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tiziana Life Sciences
Company Location: Europe
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Thymoma|Hepatocellular Carcinoma|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05651269 |
TILS-020 | P2 |
Unknown status |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2024-12-01 |
45% |
2025-06-03 |
Primary Endpoints|Treatments|Trial Status |
2017-000144-18 |
Ph IIA Study of Milciclib in Patients with Unresectable/Metastatic HCC | P2 |
Completed |
Hepatocellular Carcinoma |
2019-06-20 |
50% |
2022-03-13 |
Treatments |
NCT03109886 |
CDKO-125a-010 | P2 |
Completed |
Hepatocellular Carcinoma |
2019-05-16 |
50% |
2022-12-06 |
Primary Endpoints|Treatments |
2013-000344-25 |
2013-000344-25 | P2 |
Terminated |
Thymoma |
2017-09-26 |
2022-03-13 |
Treatments |
|
NCT01301391 |
CDKO-125a-007 | P2 |
Terminated |
Thymoma |
2017-05-31 |
50% |
2022-12-06 |
Primary Endpoints|Treatments |
NCT01011439 |
CDKO-125a-006 | P2 |
Terminated |
Thymoma |
2017-05-31 |
7% |
2022-12-06 |
Primary Endpoints |